New saRNA reporter constructs now available:
Discover TriLink’s eGFP and FLuc saRNAs: engineered for efficient intracellular amplification, longer protein expression, and low immunogenicity.
Now distributed across Europe by your prefered distributor.
As interest in self-amplifying RNA (saRNA) continues to grow within the fields of vaccine development and therapeutic innovation, the demand for high-quality, well-characterized control constructs is rising. saRNAs offer unique advantages over conventional mRNA, including intracellular amplification, longer protein expression, and greater potency at lower doses (Geall et al., 2012). To support European researchers exploring these emerging technologies, we are pleased to offer new eGFP and FLuc saRNA constructs from TriLink BioTechnologies.
These tools are designed to facilitate the validation and optimization of saRNA-based workflows with trusted, high-performance reagents, helping you explore the full potential of this RNA platform with scientific confidence.
Why Self-Amplifying RNA?
saRNA encodes both the protein of interest and viral replicase machinery, typically derived from alphavirus genomes, allowing for intracellular RNA replication after delivery. This self-replication leads to multiple rounds of antigen expression from a single RNA molecule, unlocking several downstream benefits for experimental and translational applications:
- Longer expression duration
- Greater potency at lower input doses
- Potential for co-expression of multiple genes
- Enhanced T cell responses
- Significantly higher manufacturing productivity: it may be two orders of magnitude higher than that of an mRNA vaccine platform, as discussed in an expert review (Geall et al.2022).
- This unique profile makes saRNA a strong candidate for low-dose vaccine strategies and sustained protein expression studies in both basic and applied research settings.
New: saRNA Control Constructs for eGFP and Firefly Luciferase (FLuc)
TriLink’s latest premade saRNA constructs express commonly used reporter proteins—enhanced green fluorescent protein (eGFP) and firefly luciferase (FLuc)—and are available in both unmodified and 5-methylcytidine (5mC)-modified versions:
eGFP saRNA
These constructs express enhanced green fluorescent protein (EGFP)—a direct detection marker originally derived from Aequorea victoria, emitting bright fluorescence at 509 nm.
Enhanced green fluorescent protein self-amplifying RNA Capped with CleanCap® AU analog:
Enhanced green fluorescent protein self-amplifying RNA Capped with CleanCap® AU analog, modified with 5-methylcytidine:
FLuc saRNA
Firefly luciferase, isolated from Photinus pyralis, enables sensitive bioluminescence readouts for gene expression and cell viability assays in mammalian systems.
Firefly luciferase self-amplifying RNA Capped with CleanCap® AU analog:
Firefly luciferase self-amplifying RNA Capped with CleanCap® AU analog modified with 5-methylcytidine:
Scientifically Validated Features for Improved Research Outcomes
What sets TriLink’s saRNA constructs apart is the manufacturing process, optimized for expression efficiency, low innate immune activation, and structural integrity, key concerns in saRNA-based workflows.
1. CleanCap® AU: Mimics Viral Structure for High Capping Efficiency
Explore CleanCap AU
Each construct is capped using CleanCap® AU, which mimics the authentic 5′ end of alphaviruses. This cap structure enables >95% capping efficiency, promoting efficient translation in mammalian cells and ensuring compatibility with saRNA’s viral replicon-based mechanism.
2. CleanScribe™ RNA Polymerase: Reduced dsRNA Contaminants
Explore CleanScribe
TriLink uses its proprietary CleanScribe™ RNA polymerase, which has been shown to reduce unwanted double-stranded RNA (dsRNA) by up to 85%. This minimizes the risk of activating innate immune responses, which can interfere with saRNA function and cellular viability.
3. CleanScript® saRNA IVT: Improved Yield and Integrity
All constructs are manufactured using TriLink’s CleanScript® saRNA IVT process, optimized specifically for saRNA synthesis. This method enhances RNA yield and structural integrity while minimizing by-products, delivering higher translational performance and more consistent results.
4. Optional 5-Methylcytidine (5mC) Modification
Explore 5mC
Modified versions include 5-methylcytidine, which is known to:
-
- Increase nuclease resistance
- Suppress recognition by innate immune sensors
- Improve translational efficiency in mammalian cells
As supported by recent findings, these modifications may enhance saRNA function in immunologically active environments or long-term studies.
Diana Perrier, Marketing Manager
Marketing Team at Tebubio
"With growing interest in RNA therapeutics and next-generation vaccines, self-amplifying RNA represents a powerful new class of genetic tools. These new eGFP and FLuc saRNA constructs from TriLink offer a scientifically robust, ready-to-use platform for validating saRNA technologies in vitro or in vivo."
Name goes here
Position goes here
Description goes here
-
References
Article content created by Tebubio using courtesy materials provided by TriLink Biotechnologies.
Knowledge Resources – Expand Your Expertise
Stay at the forefront of mRNA research with Tebubio’s latest insights about TriLink’s products. Read our blogs:
Ready to take the next step?
Not sure which products suits your research best? Our scientific team is here to help! From product selection to Contract Research Services (CRS), we provide expert guidance tailored to your research project needs.